Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
[This article belongs to Volume - 26, Issue - 02]

The study of the mechanism of Qinggan-27 Mongolian prescription on the database, network pharmacology, to use in traditional medicine for liver disease

Nonalcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease globally. It encompasses a spectrum ranging from simple hepatic steatosis to nonalcoholic steatohepatitis (NASH), which can progress to liver fibrosis and cirrhosis. Qinggan-27 (QG-27) is a Mongolian medicine that is widely used in liver disorders, especially non-alcoholic fatty liver disease, but experimental research on the effect of the drug on the fatty liver has not been conducted. This study, used literature and the Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform and chemical professional database, the QG-27 and the single medicinal materials of prescriptions. In our study, we created a fatty liver disease model in experimental animals and studied the effect of the QG-27. According to the qualitative analysis of thin-layer chromatography, it contains phenolic compounds phenolic acids and flavonoids. In acute toxicity, a high dose of animal showed increased heart rate, respiration, and decreased mobility. In this study was possible to create a pathological model of fatty liver in experimental animals, and it was confirmed by biochemical and histological analysis that the middle dose of the QG-27 pills reduces fatty liver. The pathological model of fatty liver was confirmed by histological analysis. The middle dose of QG-27 was effective compared to the control group and the effect of other doses.